RADX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RADX is not a good buy right now for an impatient buyer. Despite strong, catalyst-driven clinical momentum, the stock is in a clear short-term downtrend (bearish moving averages, weakening MACD) and is trading below the key pivot (5.017) and essentially on/just under support (4.874). With no Intellectia buy signals today and pattern-based odds pointing to a negative 1-month bias, the risk of near-term downside outweighs the upside of buying immediately.
Price/Trend: Current price 4.8574 (-2.21% regular; -2.81% pre-market) while the broader market is modestly down (SP500 -0.33%), indicating relative weakness today.
Momentum:
Moving averages:
Key levels:
Stat/pattern read-through:
Intellectia Proprietary Trading Signals
• Phase 2b RAD 101 interim results: 92% of participants met the primary endpoint (MRI concordance) for brain metastasis imaging—supports de-risking and improves probability of a Phase 3 path.
• Pipeline momentum: RAD 202 and RAD 204 received dose-escalation recommendations from the DSMC; RAD 202 moving to 75mCi.
• 2026 catalyst calendar: company expects significant data across multiple programs in 2026, which can attract renewed interest and re-rate the stock.
• Liquidity runway: reported cash ~ $34.52M as of Dec 31, 2025, supporting continued development.
• Technical downtrend is dominant (bearish MA stack + worsening MACD), increasing the odds that good news is already digested while price continues to drift lower.
• Near-term price weakness: trading below pivot and pressing support; if ~4.786 fails, downside acceleration risk increases.
• Event timing: final Phase 2b data expected 1H 2026 and FDA meeting planned mid-2026—meaning major validation catalysts may still be months away, while the stock can keep sliding in the interim.
• Sentiment positioning: hedge funds and insiders show no significant recent accumulation trend (neutral).
Financial data for quarterly revenue/earnings trends was not provided (financial snapshot error), so I cannot assess the latest quarter performance or specify the latest quarter season from the dataset. The only fundamental datapoint provided is cash of ~$34.52M as of Dec 31, 2025, which supports ongoing R&D spending but does not by itself indicate operating growth.
Recent Wall Street trend: consistently bullish with rising targets after clinical updates.
Pros (Street view): de-risking clinical data, multiple shots on goal across programs, and a defined upcoming catalyst path (final readouts, FDA meeting). Cons (Street view): execution and timeline risk typical of clinical-stage biotech plus the market’s sensitivity to risk-off conditions; the current tape/price action is not confirming the bullish fundamental narrative.
Influential/political trading: No recent congress trading data available; no notable politician activity was provided.
